User menu

Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations.

Bibliographic reference Hermans, C ; De Moerloose, P ; Fischer, K ; Holstein, K ; Klamroth, R ; et. al. Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations.. In: Haemophilia, Vol. 17, no.3, p. 383-92 (2011)
Permanent URL http://hdl.handle.net/2078/125234
  1. Manco-Johnson Marilyn J., Abshire Thomas C., Shapiro Amy D., Riske Brenda, Hacker Michele R., Kilcoyne Ray, Ingram J. David, Manco-Johnson Michael L., Funk Sharon, Jacobson Linda, Valentino Leonard A., Hoots W. Keith, Buchanan George R., DiMichele Donna, Recht Michael, Brown Deborah, Leissinger Cindy, Bleak Shirley, Cohen Alan, Mathew Prasad, Matsunaga Alison, Medeiros Desiree, Nugent Diane, Thomas Gregory A., Thompson Alexis A., McRedmond Kevin, Soucie J. Michael, Austin Harlan, Evatt Bruce L., Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia, 10.1056/nejmoa067659
  2. LAFEBER F. P. J. G., MIOSSEC P., VALENTINO L. A., Physiopathology of haemophilic arthropathy, 10.1111/j.1365-2516.2008.01732.x
  3. ROOSENDAAL G., JANSEN N. W. D., SCHUTGENS R., LAFEBER F. P. J. G., Haemophilic arthropathy: the importance of the earliest haemarthroses and consequences for treatment, 10.1111/j.1365-2516.2008.01882.x
  4. Valentino Leonard A., Hakobyan Narine, Enockson Candace, Blood-Induced Joint Disease: The Confluence of Dysregulated Oncogenes, Inflammatory Signals, and Angiogenic Cues, 10.1053/j.seminhematol.2008.03.017
  5. Jansen Nathalie W. D., Roosendaal Goris, Bijlsma Johannes W. J., DeGroot Jeroen, Lafeber Floris P. J. G., Exposure of human cartilage tissue to low concentrations of blood for a short period of time leads to prolonged cartilage damage: An in vitro study, 10.1002/art.22304
  6. Jansen N W D, Roosendaal G, Bijlsma J W J, DeGroot J, Theobald M, Lafeber F P J G, Degenerated and healthy cartilage are equally vulnerable to blood-induced damage, 10.1136/ard.2007.081182
  7. Hooiveld Michel J. J., Roosendaal Goris, Jacobs Kim M. G., Vianen Marieke E., van den Berg H. Marijke, Bijlsma Johannes W. J., Lafeber Floris P. J. G., Initiation of degenerative joint damage by experimental bleeding combined with loading of the joint: A possible mechanism of hemophilic arthropathy, 10.1002/art.20284
  8. Ribbans William J., Giangrande Paul, Beeton Karen, Conservative Treatment of Hemarthrosis for Prevention of Hemophilic Synovitis : , 10.1097/00003086-199710000-00004
  9. ASTERMARK J., MORADO M., ROCINO A., VAN DEN BERG H. M., VON DEPKA M., GRINGERI A., MANTOVANI L., GARRIDO R. P., SCHIAVONI M., VILLAR A., WINDYGA J., , Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors, 10.1111/j.1365-2516.2006.01296.x
  10. Palareti Gualtiero, Leali Nicoletta, Coccheri Sergio, Poggi Mario, Manotti Cesare, D'Angelo Armando, Pengo Vittorio, Erba Nicoletta, Moia Marco, Ciavarella Nicola, Devoto Gianluigi, Berrettini Mauro, Musolesi Serena, Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT), 10.1016/s0140-6736(96)01109-9
  11. Thumboo Julian, O'Duffy J. Desmond, A prospective study of the safety of joint and soft tissue aspirations and injections in patients taking warfarin sodium, 10.1002/1529-0131(199804)41:4<736::aid-art23>3.0.co;2-p
  12. Srivastava Alok, Dose and response in haemophilia - optimization of factor replacement therapy, 10.1111/j.1365-2141.2004.05110.x
  13. Brown D. L., Hardisty R. M., Kosoy M. H., Bracken C., Antihaemophilic globulin: preparation by an improved cryoprecipitation method and clinical use., 10.1136/bmj.2.5544.79
  14. Honig, Pediatrics, 43, 26 (1969)
  15. Britton Marcia, Harrison Janet, Abildgaard Charles F., Early treatment of hemophilic hemarthroses withminimal dose of new factor VIII concentrate, 10.1016/s0022-3476(74)80405-1
  16. Abildgaard, Semin Hematol, 12, 223 (1975)
  17. Ashenhurst, Blood, 50, 181 (1977)
  18. Lower Doses of Factor VIII for Hemophilia, 10.1056/nejm197708182970724
  19. Doses of Factor VIII for Hemophilic Bleeding, 10.1056/nejm197712012972218
  20. Ripa, Blood, 51, 763 (1978)
  21. Allain, Thromb Haemost, 42, 825 (1979)
  22. Stirling M.L., Prescott R.J., MINIMUM EFFECTIVE DOSE OF INTERMEDIATE FACTOR-VIII CONCENTRATE IN HÆMOPHILIACS ON HOME THERAPY, 10.1016/s0140-6736(79)91328-x
  23. Aronstam A., Choudhury D.P., Wassef M., Turk P.M., Mclellan D.S., DOUBLE-BLIND CONTROLLED TRIAL OF THREE DOSAGE REGIMENS IN TREATMENT OF HÆMARTHROSES IN HÆMOPHILIA A, 10.1016/s0140-6736(80)90659-5
  24. Aronstam A., Wassef M., Hamad Z., Aston D.L., The identification of high-risk elbow hemorrhages in adolescents with severe hemophilia A, 10.1016/s0022-3476(81)80844-x
  25. Aronstam A, Wassef M, Hamad Z, Low doses of factor VIII for selected ankle bleeds in severe haemophilia A., 10.1136/bmj.284.6318.790
  26. Bray, Blood, 83, 2428 (1994)
  27. Abshire, Thromb Haemost, 83, 811 (2000)
  28. Courter S.G, Bedrosian C.L, Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients, 10.1016/s0037-1963(01)90108-8
  29. Rothschild C., Scharrer I., Brackmann H.-H., Stieltjes N., Vicariot M., Torchet M.-F., Effenberger W., European data of a clinical trial with a sucrose formulated recombinant factor VIII in previously treated haemophilia A patients, 10.1046/j.1351-8216.2001.00131.x
  30. World Federation of Haemophilia, Guidelines for the Management of Haemophilia (2009)
  31. Medical Advisory Committee of Haemophilia Foundation of New Zealand, National Guidelines - Management of Haemophilia (2009)
  32. Lee C. A., Kessler C. M., Varon D., Martinowitz U., Heim M., GRINGERI A., , Treatment protocol of haemophilia and other congenital bleeding disorders in Italy, 10.1046/j.1365-2516.1998.4404213.x
  33. Santagostino, Mannucci, Bianchi Bonomi, Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy, 10.1046/j.1365-2516.2000.00361.x
  34. GREHCO (Groupe de Recherche et d’Etudes de l’Hémophilie du Centre et de l’Ouest), Le traitement de l’hémophilie (2002)
  35. Bundesärztekammer (German Medical Association), Querschnitts-Leitlinien (BAK) zur Therapie mit blutkomponenten und Plasmaderivaten, 170 (2009)
  36. Lee C. A., Kessler C. M., Varon D., Martinowitz U., Heim M., BERNTORP E., Guidelines on treatment of haemophilia in Sweden, 10.1046/j.1365-2516.1998.4404214.x
  37. Mahlangu, S Afr Med J, 98, 126 (2008)
  38. Kasper, Haemophilia, 6, 84 (2000)
  39. Lee C. A., Kessler C. M., Varon D., Martinowitz U., Heim M., SRIVASTAVA A., CHUANSUMRIT A., CHANDY M., DURAISWAMY G., KARAGUS C., Management of haemophilia in the developing world, 10.1046/j.1365-2516.1998.440474.x
  40. Elander J., Barry T., Analgesic use and pain coping among patients with haemophilia, 10.1046/j.1365-2516.2003.00723.x
  41. VAN VEEN J. J., GLEESON D. C., MAKRIS M., Paracetamol/acetaminophen usage in haemophilia: more caution needed?, 10.1111/j.1365-2516.2008.01653.x
  42. RATTRAY B., NUGENT D. J., YOUNG G., Celecoxib in the treatment of haemophilic synovitis, target joints, and pain in adults and children with haemophilia, 10.1111/j.1365-2516.2006.01311.x
  43. Tsoukas C., Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy, 10.1182/blood-2004-09-3501
  44. Rattray B., Nugent D. J., Young G., Rofecoxib as adjunctive therapy for haemophilic arthropathy, 10.1111/j.1365-2516.2005.01087.x
  45. Solomon, Curr Opin Cardiol, 21, 613 (2006)
  46. Shupak R., Teitel J., Garvey M. B., Freedman J., Intraarticular methylprednisolone therapy in hemophilic arthropathy, 10.1002/ajh.2830270107
  47. Management of Hemarthrosis, 10.1056/nejm197005212822123
  48. Kisker C. T., Burke Carolyn, Double-Blind Studies on the Use of Steroids in the Treatment of Acute Hemarthrosis in Patients with Hemophilia, 10.1056/nejm197003192821201
  49. Magistro, Phys Ther, 44, 169 (1964)
  50. Gandini, Electrodiagn Ther, 14, 99 (1977)
  51. Costello Charles T, Jeske Arthur H, Iontophoresis: Applications in Transdermal Medication Delivery, 10.1093/ptj/75.6.554
  52. Rodriguez-Merchan, The Treatment of Haemophilia (World Federation of Haemophilia Monograph), 23, 1 (2008)
  53. Cazenave, J Chir (Paris), 127, 522 (1990)
  54. Sarimo, Scand J Surg, 91, 361 (2002)
  55. Kerr, Bibl Haematol, 23, 1319 (1965)
  56. Ingram G I, Mathews J A, Bennett A E, Controlled trial of joint aspiration in acute haemophilic haemarthrosis., 10.1136/ard.31.5.423-a
  57. Banta, West J Med, 122, 285 (1975)
  58. ROBERTSON J. D., CONNOLLY B., HILLIARD P., WEDGE J., BABYN P., CARCAO M., Acute haemarthrosis of the hip joint: rapid convalescence following ultrasound-guided needle aspiration, 10.1111/j.1365-2516.2008.01854.x
  59. Gregg, Physiotherapy, 50, 394 (1964)
  60. dYOUNG A. I., Domiciliary application of CryoCuff in severe haemophilia: qualitative questionnaire and clinical audit, 10.1111/j.1365-2516.2008.01701.x
  61. Wilson, J Bone Joint Surg Br, 69, 103 (1987)
  62. Mauser-Bunschoten E. P., Successful treatment of severe bleeding in hemophilic target joints by selective angiographic embolization, 10.1182/blood-2004-06-2063
  63. KLAMROTH R., GOTTSTEIN S., ESSERS E., LANDGRAF H., WILASCHEK M., OLDENBURG J., Successful angiographic embolization of recurrent elbow and knee joint bleeds in seven patients with severe haemophilia, 10.1111/j.1365-2516.2008.01842.x
  64. DONFIELD S. M., ASTERMARK J., LAIL A. E., GILBERT S. A., BERNTORP E., , Value added: increasing the power to assess treatment outcome in joint haemorrhages, 10.1111/j.1365-2516.2007.01638.x